Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/9/2018
SIETES contiene 92557 citas

 
 
 1 a 20 de 26 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, García-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018:26 de agosto. [Ref.ID 102827]
2. Cita con resumen
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22. [Ref.ID 101586]
3. Cita con resumen
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97. [Ref.ID 100769]
4. Cita con resumen
O'Donoghue ML, Glaser R, Cavender MA, Alyward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KAA, Gutierrez JAT, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay J-F, Ruda M, Steg G, Theoux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA, for the LATITUDE-TIMI 60 Investigators. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction. A randomized clinical trial. JAMA 2016;315:1591-9. [Ref.ID 100240]
5.Tiene citas relacionadas
Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet 2015;386:292-302. [Ref.ID 99357]
6. Cita con resumen
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzylio W, De Lucca P, Im K, Bohula EA, Reist CJ, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97. [Ref.ID 99298]
7.Tiene citas relacionadas Cita con resumen
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800. [Ref.ID 99086]
8.Tiene citas relacionadas Cita con resumen
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Med M, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. [Ref.ID 99056]
9.Tiene citas relacionadas Cita con resumen
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand S-LT, Braunwald E, Wiviott SD, Cohen DJ, Holmes Jr DR, Krucoff MW, Hermiller J, Dauerman HL, Simon Di, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, for the DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66. [Ref.ID 98420]
10. Cita con resumen
O'Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Cannon CP, Serruys PW, for the SOLID-TIMI 52 Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome.The SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312:1006-15. [Ref.ID 97951]
11.Tiene citas relacionadas Cita con resumen
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Atnman EM, for the ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104. [Ref.ID 96608]
12.Tiene citas relacionadas Cita con resumen
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. [Ref.ID 96330]
13.Tiene citas relacionadas
Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran DJ, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzylio W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 2013;382:605-13. [Ref.ID 96025]
14. Cita con resumen
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJO, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA, for the TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13. [Ref.ID 92750]
15. Cita con resumen
Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KAA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FWA, Gibson CM, for the ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19. [Ref.ID 92103]
16.Tiene citas relacionadas Cita con resumen
Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann F-J, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. A meta-analysis. JAMA 2010;304:1821-30. [Ref.ID 89227]
17.Tiene citas relacionadas Cita con resumen
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Wiviott SD. Combination therapy with clopidogrel and proton-pump inhibitors. Authors' reply. Lancet 2010;375:28-9. [Ref.ID 87529]
18.Tiene citas relacionadas Cita con resumen
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97. [Ref.ID 86536]
19. Cita con resumen
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sbatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-60. [Ref.ID 86007]
20.Tiene citas relacionadas
Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Antman EM. Prasugrel STEMI subgroup analysis. Authors' reply. Lancet 2009;373:1846-8. [Ref.ID 85952]
Seleccionar todas
 
 1 a 20 de 26 siguiente >>